A relatively small but growing number of drug developers are monetizing their royalties/revenues by selling off all or part of these income streams to investors. If done prior to launch, these deals can protect against downside risk of the product not being a commercial success. But royalty/revenue monetization is still a relatively expensive source of capital, compared to raising conventional debt, if that is a possibility. Click here for more pros and cons. The amount of capital provided for royalty/revenue monetization deals over the past five years has doubled since between 2000 and 2005. Tell us if you would tap into this source of capital.

Poll Question:
Do you think entering royalty and revenue monetization transactions is a good strategy for a cash-strapped firm?




Previous articleContest: Who Is the Steve Jobs of Biotechnology?
Next articleScientists Describe Top-Down Approach to Identifying Individual Protein Isoforms on a Proteome-Wide Scale